Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Targets |
HDAC1
|
---|---|
ln Vitro |
In the three-dimensional model of the human HDAC1 protein, 9-Hydroxyoctadecanoic acid (9-HSA) can bind to the active site [1]. Increased transcription and translation of p21WAF1 is observed upon exposure to 100 μM of 9-Hydroxyoctadecanoic acid (9-HSA) over 24 hours, which also causes G0/G1 arrest and reduces the proliferation of HT29 cells [2].
|
Cell Assay |
Cell Proliferation Assay[1].
Cell Types: HT29 cell Tested Concentrations: 100 μM Incubation Duration: 24 h Experimental Results: Resulted in a significant inhibition of cell proliferation. Cell Cycle Analysis[1]. Cell Types: HT29 cell Tested Concentrations: 100 μM Incubation Duration: 24 h Experimental Results: diminished S-phase activity by 50.2% compared with untreated controls, and the growth inhibition was associated with a strong arrest in G0/G1. Western Blot Analysis[1]. Cell Types: HT29 cell Tested Concentrations: 100 μM Incubation Duration: 24 h Experimental Results: Increased the expression of p21WAF1. RT-PCR[1]. Cell Types: HT29 cell Tested Concentrations: 100 μM Incubation Duration: 24 h Experimental Results: Induced p21WAF1 tanscript. |
References |
[1]. Calonghi N, et al. Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer. J Lipid Res. 2005 Aug;46(8):1596-603.
[2]. Calonghi N, et al. 9-Hydroxystearic acid upregulates p21(WAF1) in HT29 cancer cells. Biochem Biophys Res Commun. 2004 Jan 30;314(1):138-42. |
Molecular Formula |
C18H36O3
|
---|---|
Molecular Weight |
300.48
|
CAS # |
3384-24-5
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
OC(CCCCCCCCC)CCCCCCCC(O)=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (332.80 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3280 mL | 16.6400 mL | 33.2801 mL | |
5 mM | 0.6656 mL | 3.3280 mL | 6.6560 mL | |
10 mM | 0.3328 mL | 1.6640 mL | 3.3280 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.